Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by RenovoRx, Inc.
< Previous
1
2
Next >
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
May 02, 2024
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
April 16, 2024
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
April 15, 2024
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Announces $11.1 Million at Market Private Placement
April 08, 2024
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
April 05, 2024
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
March 12, 2024
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Highlights Key Leadership Promotions
March 08, 2024
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx CEO Issues Letter to Shareholders
February 06, 2024
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Closes $6.1 Million Private Placement
January 29, 2024
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
December 21, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
December 19, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
December 13, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
November 16, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
November 14, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
October 02, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
August 17, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
July 31, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
July 20, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
ASX:IMU
RNXT
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
June 29, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
June 20, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15
June 12, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial
June 01, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer
May 25, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Present at the LD Micro Invitational XIII Conference
May 24, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
May 15, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event
May 01, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023
April 28, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
April 27, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
April 14, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
April 11, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.